#USA #MedTech #Veeva Systems #Barcelona #Clinical Trials

Veeva MedTech: Setting New Standards in Clinical Trials

In a significant move for the medical technology sector, Veeva Systems (NYSE: VEEV) recently announced that over 50 medtech companies have adopted its Clinical Platform. This includes 11 of the top 20 companies and seven leading Clinical Research Organizations (CROs). The shift to Veeva MedTech signifies a crucial pivot away from traditional methods towards modern and connected solutions tailored for clinical trials of medical devices and diagnostics.

Bridging the Gap in Clinical Efficiency

As regulatory requirements evolve and the medtech landscape becomes increasingly competitive, companies are realizing the necessity for streamlined processes. Veeva MedTech offers a comprehensive infrastructure that helps organizations scale operations while ensuring compliance with local, regional, and international regulations. The adoption of Veeva’s solutions has reportedly led to a 50% reduction in development times for studies utilizing Veeva EDC and an 80% decrease in document redundancy with Veeva eTMF.

Kevin Liang, Vice President of Clinical Strategy at Veeva MedTech, expressed enthusiasm about the collaboration with the industry: "It's exciting to partner with leading medtech firms in transitioning to Veeva MedTech, enabling execution and innovation of clinical studies that can deliver life-changing products faster."

Industry Insights: Testimonials from Medical Companies

Numerous industry representatives have shared positive feedback regarding their experience with Veeva EDC and its impact on their clinical operations:

• - Leianne Ebert, Director of Clinical Data Operations at Alcon, stated: "Our collaboration with Veeva EDC has significantly improved our global library by establishing reusable standards, achieving 50% standardization in just one year. This greatly enhances our compliance efforts."

• - Kimberly Dorsch, Global Vice President of Clinical Affairs at LifeNet Health, emphasized the consistency of data collection: "Regardless of whether we conduct a registrational study or an IDE/IND study supporting a PMA/BLA, Veeva ensures we collect data consistently and in full regulatory compliance."

• - Matt Christensen, Senior Vice President of Global Clinical and Medical Affairs at Smith+Nephew, noted the efficiencies gained through Veeva eTMF: "Post-implementation, we reduced our QA time by over 90% and significantly improved our document creation timelines."

Looking Forward: Veeva's Commitment to Innovation

The role of technology in clinical trials is not just about compliance; it is about fostering improvements that lead to better health outcomes. Many medical technology companies, large and small, are utilizing Veeva's platform to propel their innovations. The increasing number of clinical trials utilizing Veeva solutions demonstrates an industry-wide acknowledgment of the benefits of connected, modern applications.

For more details on Veeva's Clinical Platform tailored for medical technology, you can visit veeva.com/MedTechClinical.

About Veeva Systems

Veeva stands as a leader in cloud software for the life sciences industry, dedicated to innovation and customer success with over 1,000 clients ranging from the world's top biopharmaceutical firms to emerging biotech companies. As a Public Benefit Corporation, Veeva aims to balance stakeholder interests, ensuring that its contributions positively impact customers, employees, and the broader medtech field.

In conclusion, the integration of Veeva MedTech's applications not only equips companies with essential tools tailored for today's challenges but also inspires a new wave of advancements that could redefine clinical trials in the medtech sector. Companies can look forward to improved operational outcomes and faster delivery of life-saving innovations to patients worldwide.